IP Library Granted Patent US 8,008,017
Granted Patent B2
US 8,008,017 · App. 12/555,679 · Granted Aug 30, 2011

Compositions and methods for detecting the presence of cryptosporidium organisms in a test sample

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,008,017
App. No.
12/555,679
Granted
Aug 30, 2011
Kind
B2
Abstract

The present invention describes novel oligonucleotides targeted to nucleic acid sequences derived from Cryptosporidium organisms, and Cryptosporidium parvum organisms in particular, which are useful for determining the presence of Cryptosporidium organisms in a test sample. The oligonucleotides of the present invention include hybridization assay probes, helper probes and amplification primers. The present invention further describes a novel method for obtaining purified ribonucleic acid from viable oocysts.

Claims (17)

1. A probe comprising a detectable label and a target binding region that fully hybridizes to a target sequence present in target nucleic acid derived from Cryptosporidium organisms in a test sample under stringent conditions to form a probe:target hybrid stable for detection, the target sequence being selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, wherein the probe does not comprise a base region in addition to the target binding region that is capable of stably binding to the target nucleic acid under the stringent conditions, and wherein the probe does not hybridize to nucleic acid derived from a non- Cryptosporidium organism in the test sample to form a probe:non-target hybrid stable for detection under the conditions.

2. The probe of claim 1 , wherein the base sequence of the target binding region of the probe is perfectly complementary to the base sequence of the target sequence.

3. The probe of claim 1 , wherein the base sequence of the probe is perfectly complementary to the base sequence of the target sequence.

4. The probe hybridization reagent of claim 1 , wherein the probe comprises at least one base region that does not stably hybridize to nucleic acid derived from Cryptosporidium organisms under the stringent conditions.

5. The probe of claim 1 , wherein the target binding region of the probe includes at least one ribonucleotide modified to include a 2′-O-methyl substitution to the ribofuranosyl moiety.

6. The probe of claim 1 , wherein the stringent conditions comprise 50 mM succinic acid, 1% (w/v) LLS, 7.5 mM aldrithiol-2, 0.6 M LiC1, 115 mM LiOH, 10 mM EDTA, 10 mM EGTA, 1.5% (v/v) ethyl alcohol (absolute), pH to 4.7, and a test sample temperature of about 60° C.

7. A probe mix comprising the probe of claim 1 and a first helper oligonucleotide, the base sequence of the first helper oligonucleotide being selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 and SEQ ID NO:27.

8. The probe mix of claim 7 further comprising a second helper oligonucleotide, the base sequence of the second helper oligonucleotide being selected from the group consisting of SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26 and SEQ ID NO:28.

9. A method for determining the presence of Cryptosporidium organisms in a test sample, the method comprising the steps of:

providing to the test sample the probe of claim 1 under stringent conditions; and

determining whether a probe:target hybrid has formed as an indication of the presence of Cryptosporidium organisms in the test sample.

10. The method of claim 9 , wherein the base sequence of the target binding region of the probe is perfectly complementary to the base sequence of the target sequence.

11. The method of claim 9 , wherein the base sequence of the probe is perfectly complementary to the base sequence of the target sequence.

12. The method of claim 9 , wherein the probe comprises at least one base region that does not stably hybridize to nucleic acid derived from Cryptosporidium organisms under the stringent conditions.

13. The method of claim 9 , wherein the target binding region includes at least one ribonucleotide modified to include a 2′-O-methyl substitution to the ribofuranosyl moiety.

14. A hybridization reagent containing, free in solution, the probe of claim 1 .

15. The method of claim 9 , wherein the probe is provided to the test sample in a hybridization reagent in which the probe is free in solution.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →